FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136989176> ?p ?o ?g. }

• W3136989176 abstract "Purposes: Nuciferine, a main aporphine alkaloid component found in lotus leaf ( Nelumbo nucifera ), has been demonstrated to possess the property of reducing fat mass and alleviating dyslipidemia in vivo . The purpose of this study is to explore the effects of nuciferine on the proliferation and differentiation of 3T3-L1 cells and further investigate the possible underlying molecular mechanisms. Methods: 3T3-L1 preadipocytes were treated with 0∼20 μM nuciferine for 24∼120 h, the cell viability was assessed using CCK8. 3T3-L1 preadipocytes and human primary preadipocytes were then induced differentiation and the effects of nuciferine on the lipid metabolism in differentiating and fully differentiated adipocytes were observed by the methods of intracellular triglyceride (TG) assay, Oil Red O staining, RT-qPCR and western blot. Transient transfection and dual luciferase reporter gene methods were used to assess the effects of nuciferine on FAS promoter activities. Results: Nuciferine inhibited the proliferation of 3T3-L1 preadipocytes in a dose- and time-dependent manner. 20 μM nuciferine significantly attenuated lipid accumulation and reduced intracellular TG contents by 47.2, 59.9 and 55.4% on the third, sixth and ninth day of preadipocytes differentiation, respectively (all p &lt; 0.05). Moreover, the mRNA levels of PPARγ, C/EBPα, C/EBPβ, FAS, ACC, HSL and ATGL were notably decreased by 39.2∼92.5% in differentiating preadipocytes when treated with 5∼20 μM nuciferine (all p &lt; 0.05). In fully differentiated adipocytes treated with 20 μM nuciferine for 48 h, the mRNA levels of FAS, ACC and SREBP1 were remarkably downregulated by 22.6∼45.2% compared with the controls (0 μM) (all p &lt; 0.05), whereas the expression of adipokines FGF21 and ZAG were notably promoted by nuciferine. Similarly, in fully differentiated human primary adipocytes, the mRNA levels of FAS, ACC, SREBP1 were decreased and the expression of FGF21 and ZAG were elevated after treated with nuciferine (all p &lt; 0.05). Further mechanism studies showed that 2.5∼20 μM nuciferine significantly decreased FAS promoter activities in 3T3-L1 preadipocytes. Conclusion: Nuciferine inhibited the proliferation and differentiation of 3T3-L1 preadipocytes. The inhibitory effects of nuciferine on adipogenesis might be due to the downregulation of PPARγ, C/EBPα and C/EBPβ, which led to the reduction of intracellular lipid accumulation in 3T3-L1 cells and by downregulating the expression of critical lipogenic enzymes, especially of FAS, which was achieved by inhibiting the FAS promoter activities. Besides, nuciferine promoted the expression of adipokines in fully differentiated adipocytes." @default.
• W3136989176 created "2021-03-29" @default.
• W3136989176 creator A5021972817 @default.
• W3136989176 creator A5042656907 @default.
• W3136989176 creator A5053337653 @default.
• W3136989176 creator A5054551633 @default.
• W3136989176 creator A5067545412 @default.
• W3136989176 creator A5068009587 @default.
• W3136989176 creator A5080400481 @default.
• W3136989176 creator A5085187324 @default.
• W3136989176 date "2021-03-22" @default.
• W3136989176 modified "2023-10-16" @default.
• W3136989176 title "Nuciferine Inhibited the Differentiation and Lipid Accumulation of 3T3-L1 Preadipocytes by Regulating the Expression of Lipogenic Genes and Adipokines" @default.
• W3136989176 cites W1963897417 @default.
• W3136989176 cites W1969259827 @default.
• W3136989176 cites W1973295099 @default.
• W3136989176 cites W1980056186 @default.
• W3136989176 cites W1981827427 @default.
• W3136989176 cites W1991426730 @default.
• W3136989176 cites W2010438605 @default.
• W3136989176 cites W2025536516 @default.
• W3136989176 cites W2033580378 @default.
• W3136989176 cites W2046562373 @default.
• W3136989176 cites W2046658782 @default.
• W3136989176 cites W2049962336 @default.
• W3136989176 cites W2051051060 @default.
• W3136989176 cites W2060282672 @default.
• W3136989176 cites W2065678808 @default.
• W3136989176 cites W2083056430 @default.
• W3136989176 cites W2101951807 @default.
• W3136989176 cites W2119103707 @default.
• W3136989176 cites W2123652234 @default.
• W3136989176 cites W2132596222 @default.
• W3136989176 cites W2139303139 @default.
• W3136989176 cites W2139470429 @default.
• W3136989176 cites W2152727172 @default.
• W3136989176 cites W2155008771 @default.
• W3136989176 cites W2158760478 @default.
• W3136989176 cites W2200889199 @default.
• W3136989176 cites W2207242414 @default.
• W3136989176 cites W2397067342 @default.
• W3136989176 cites W2402297387 @default.
• W3136989176 cites W2434000198 @default.
• W3136989176 cites W2522814719 @default.
• W3136989176 cites W2525023887 @default.
• W3136989176 cites W2526536530 @default.
• W3136989176 cites W2615990196 @default.
• W3136989176 cites W2631665201 @default.
• W3136989176 cites W2773351837 @default.
• W3136989176 cites W2791446485 @default.
• W3136989176 cites W2806655879 @default.
• W3136989176 cites W2894233329 @default.
• W3136989176 cites W2898942138 @default.
• W3136989176 cites W2908052005 @default.
• W3136989176 cites W2914391590 @default.
• W3136989176 cites W2935381344 @default.
• W3136989176 cites W2937928544 @default.
• W3136989176 cites W2944333152 @default.
• W3136989176 cites W2944549000 @default.
• W3136989176 cites W2978687867 @default.
• W3136989176 cites W2979547869 @default.
• W3136989176 cites W2982593414 @default.
• W3136989176 cites W3013801749 @default.
• W3136989176 cites W3019639899 @default.
• W3136989176 cites W3020225906 @default.
• W3136989176 cites W3081140465 @default.
• W3136989176 cites W3088261834 @default.
• W3136989176 doi "https://doi.org/10.3389/fphar.2021.632236" @default.
• W3136989176 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8025837" @default.
• W3136989176 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33841152" @default.
• W3136989176 hasPublicationYear "2021" @default.
• W3136989176 type Work @default.
• W3136989176 sameAs 3136989176 @default.
• W3136989176 citedByCount "15" @default.
• W3136989176 countsByYear W31369891762021 @default.
• W3136989176 countsByYear W31369891762022 @default.
• W3136989176 countsByYear W31369891762023 @default.
• W3136989176 crossrefType "journal-article" @default.
• W3136989176 hasAuthorship W3136989176A5021972817 @default.
• W3136989176 hasAuthorship W3136989176A5042656907 @default.
• W3136989176 hasAuthorship W3136989176A5053337653 @default.
• W3136989176 hasAuthorship W3136989176A5054551633 @default.
• W3136989176 hasAuthorship W3136989176A5067545412 @default.
• W3136989176 hasAuthorship W3136989176A5068009587 @default.
• W3136989176 hasAuthorship W3136989176A5080400481 @default.
• W3136989176 hasAuthorship W3136989176A5085187324 @default.
• W3136989176 hasBestOaLocation W31369891761 @default.
• W3136989176 hasConcept C122927707 @default.
• W3136989176 hasConcept C126322002 @default.
• W3136989176 hasConcept C134018914 @default.
• W3136989176 hasConcept C142536801 @default.
• W3136989176 hasConcept C171089720 @default.
• W3136989176 hasConcept C185592680 @default.
• W3136989176 hasConcept C25095133 @default.
• W3136989176 hasConcept C2776175234 @default.
• W3136989176 hasConcept C2780806160 @default.
• W3136989176 hasConcept C4733338 @default.
• W3136989176 hasConcept C55493867 @default.
• W3136989176 hasConcept C71924100 @default.
• W3136989176 hasConcept C86803240 @default.

• next